VTE Risk After Joint Replacement: Does Anticoagulant Choice Matter?
Among younger patients undergoing total hip or knee replacement, whether they received aspirin versus direct oral anticoagulants (DOACs) did not seem to affect their risk
Among younger patients undergoing total hip or knee replacement, whether they received aspirin versus direct oral anticoagulants (DOACs) did not seem to affect their risk
Treatment with single-agent pirtobrutinib (Jaypirca), a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, showed encouraging efficacy with a tolerable safety profile in a cohort of heavily
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up here. CHICAGO